Search Results - "Marcucci, Katherine T."

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells by Fraietta, Joseph A., Nobles, Christopher L., Sammons, Morgan A., Lundh, Stefan, Carty, Shannon A., Reich, Tyler J., Cogdill, Alexandria P., Morrissette, Jennifer J. D., DeNizio, Jamie E., Reddy, Shantan, Hwang, Young, Gohil, Mercy, Kulikovskaya, Irina, Nazimuddin, Farzana, Gupta, Minnal, Chen, Fang, Everett, John K., Alexander, Katherine A., Lin-Shiao, Enrique, Gee, Marvin H., Liu, Xiaojun, Young, Regina M., Ambrose, David, Wang, Yan, Xu, Jun, Jordan, Martha S., Marcucci, Katherine T., Levine, Bruce L., Garcia, K. Christopher, Zhao, Yangbing, Kalos, Michael, Porter, David L., Kohli, Rahul M., Lacey, Simon F., Berger, Shelley L., Bushman, Frederic D., June, Carl H., Melenhorst, J. Joseph

“…Cancer immunotherapy based on genetically redirecting T cells has been used successfully to treat B cell malignancies 1 – 3 . In this strategy, the T cell…”
Get full text

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia by Porter, David L, Hwang, Wei-Ting, Frey, Noelle V, Lacey, Simon F, Shaw, Pamela A, Loren, Alison W, Bagg, Adam, Marcucci, Katherine T, Shen, Angela, Gonzalez, Vanessa, Ambrose, David, Grupp, Stephan A, Chew, Anne, Zheng, Zhaohui, Milone, Michael C, Levine, Bruce L, Melenhorst, Jan J, June, Carl H

“…Patients with multiply relapsed or refractory chronic lymphocytic leukemia (CLL) have a poor prognosis. Chimeric antigen receptor (CAR)-modified T cells…”
Get more information

Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients by Marcucci, Katherine T., Jadlowsky, Julie K., Hwang, Wei-Ting, Suhoski-Davis, Megan, Gonzalez, Vanessa E., Kulikovskaya, Irina, Gupta, Minnal, Lacey, Simon F., Plesa, Gabriela, Chew, Anne, Melenhorst, J. Joseph, Levine, Bruce L., June, Carl H.

“…Replication-competent retrovirus/lentivirus (RCR/L) and insertional oncogenesis are potential safety risks with integrating viruses in gene-modified cell…”
Get full text

BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia by Kong, Weimin, Dimitri, Alexander, Wang, Wenliang, Jung, In-Young, Ott, Christopher J, Fasolino, Maria, Wang, Yan, Kulikovskaya, Irina, Gupta, Minnal, Yoder, Todd, DeNizio, Jamie E, Everett, John K, Williams, Erik F, Xu, Jun, Scholler, John, Reich, Tyler J, Bhoj, Vijay G, Haines, Kathleen M, Maus, Marcela V, Melenhorst, J. Joseph, Young, Regina M, Jadlowsky, Julie K, Marcucci, Katherine T, Bradner, James E, Levine, Bruce L, Porter, David L, Bushman, Frederic D, Kohli, Rahul M, June, Carl H, Davis, Megan M, Lacey, Simon F, Vahedi, Golnaz, Fraietta, Joseph A

“…Chimeric antigen receptor (CAR) T cells have induced remarkable antitumor responses in B cell malignancies. Some patients do not respond because of T cell…”
Get full text

Identification of two distinct structural regions in a human porcine endogenous retrovirus receptor, HuPAR2, contributing to function for viral entry by Marcucci, Katherine T, Argaw, Takele, Wilson, Carolyn A, Salomon, Daniel R

“…Of the three subclasses of Porcine Endogenous Retrovirus (PERV), PERV-A is able to infect human cells via one of two receptors, HuPAR1 or HuPAR2…”
Get full text

Comparison of the convergent receptor utilization of a retargeted feline leukemia virus envelope with a naturally-occurring porcine endogenous retrovirus A by Mazari, Peter M, Argaw, Takele, Valdivieso, Leonardo, Zhang, Xia, Marcucci, Katherine T, Salomon, Daniel R, Wilson, Carolyn A, Roth, Monica J

“…Abstract In vitro screening of randomized FeLV Envelope libraries identified the CP isolate, which enters cells through HuPAR-1, one of two human receptors…”
Get full text

Functional hierarchy of two L domains in porcine endogenous retrovirus (PERV) that influence release and infectivity by Marcucci, Katherine T, Martina, Yuri, Harrison, Frank, Wilson, Carolyn A, Salomon, Daniel R

“…Abstract The porcine endogenous retrovirus (PERV) Gag protein contains two late (L) domain motifs, PPPY and P(F/S)AP. Using viral release assays we demonstrate…”
Get full text

Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia by Mueller, Karen Thudium, Chakraborty, Abhijit, Wood, Patricia A, Awasthi, Rakesh, Quintas-Cardama, Alfonso, Han, Xia, Maude, Shannon L, Grupp, Stephan A., Porter, David L, Frey, Noelle, Marcucci, Katherine T., Levine, Bruce L, Melenhorst, Jan J., June, Carl H, Lacey, Simon F.

“…▪ Introduction CTL019 is a novel, investigational, chimeric antigen receptor (CAR) immunotherapy whereby autologous T cells are genetically modified with a…”
Get full text

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy by Chong, Elise A., Svoboda, Jakub, Nasta, Sunita Dwivedy, Porter, David L., Winchell, Nicole, Landsburg, Daniel J., Mato, Anthony R., Lacey, Simon F., Melenhorst, Jan J., Chew, Anne, Hasskarl, Jens, Marcucci, Katherine T., Levine, Bruce L, June, Carl H, Schuster, Stephen J.

“…BACKGROUND: Patients (pts) with follicular lymphoma (FL) who have progression of disease within 2 years of immunochemotherapy have poor outcomes and represent…”
Get full text

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models by Ruella, Marco, Maude, Shannon L, Engels, Boris, Barrett, David M., Frey, Noelle, Marcucci, Katherine T, Shestova, Olga, Singh, Nathan, Perazzelli, Jessica, Christian, David A, Haagen, Dana, Lacey, Simon F, Melenhorst, J. Joseph, Brogdon, Jennifer, Young, Regina M, Porter, David L, June, Carl H, Grupp, Stephan A, Gill, Saar I.

“…Introduction. Anti-CD19 chimeric antigen receptor T cells (CART19 or CTL019) have shown impressive clinical activity in B-cell acute lymphoblastic leukemia…”
Get full text

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia by Maude, Shannon L, Hucks, George E, Callahan, Colleen, Baniewicz, Diane, Fasano, Christina, Barker, Christine, Rheingold, Susan R., Aplenc, Richard, Dinofia, Amanda M., Li, Amanda, Teachey, David T, Barrett, David M., Brogdon, Jennifer, Young, Regina M, Scholler, John, Marcucci, Katherine T, Levine, Bruce L, Frey, Noelle, Porter, David L, Lacey, Simon F, Melenhorst, J. Joseph, June, Carl H, Grupp, Stephan A

“…Background Chimeric antigen receptor (CAR)-modified T cells targeting CD19 can induce potent and sustained responses in children with relapsed/refractory acute…”
Get full text

Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL) by Svoboda, Jakub, Rheingold, Susan R., Gill, Saar I, Grupp, Stephan A, Lacey, Simon F, Melenhorst, J. Joseph, Kulikovskaya, Irina, Loudon, Brandon, Kerr, Naseem, Marcucci, Katherine T, Shea, Kim-Marie, Schmidt, Aliza, Lledo, Lester, Marshall, Amy, Mato, Anthony R., Dwivedy Nasta, Sunita, Landsburg, Daniel J., Youngman, Matthew R., Levine, Bruce L, Porter, David L, June, Carl H, Schuster, Stephen J.

“…Background: Cellular therapy using anti-CD19 autologous chimeric antigen receptor modified T (CART19) cells demonstrates promising outcomes in several…”
Get full text

Clinical Evidence That Deficiency of the Methylcytosine Dioxygenase TET2 Gene Promotes the Clonal Expansion and Therapeutic Efficacy of CD19-Directed T Cells by Fraietta, Joseph A, Nobles, Christopher L, Sammons, Morgan A, Carty, Shannon A., Lundh, Stefan M, Reich, Tyler, Cogdill, Alexandria P, Gohil, Mercy, Morrissette, Jennifer J.D., Kulikovskaya, Irina, Nazimuddin, Farzana, Gupta, Minnal, Wang, Yan, Liu, Xiaojun, Young, Regina M, Ambrose, David E, Jordan, Martha S, Marcucci, Katherine T, Levine, Bruce L, Zhao, Yangbing, Kalos, Michael, Porter, David L, Lacey, Simon F, Berger, Shelley L, Bushman, Frederic D, June, Carl H, Melenhorst, J. Joseph

“…Adoptive transfer of autologous chimeric antigen receptor (CAR) T cells that target tumor antigens can induce remissions in patients with hematologic…”
Get full text

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia by Maude, Shannon L, Barrett, David M., Rheingold, Susan R., Aplenc, Richard, Teachey, David T, Callahan, Colleen, Baniewicz, Diane, White, Claire, Talekar, Mala K., Shaw, Pamela A, Brogdon, Jennifer L, Young, Regina M, Scholler, John, Marcucci, Katherine T., Levine, Bruce L, Frey, Noelle, Porter, David L, Lacey, Simon F., Melenhorst, J. Joseph, June, Carl H, Grupp, Stephan A.

“…▪ Background Targeted immunotherapy with CTL019, CD19-specific chimeric antigen receptor (CAR)-modified T cells, can produce potent and sustained responses in…”
Get full text

Treatment with Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) Results in Durable Remissions in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphomas of Germinal Center and Non-Germinal Center Origin, "Double Hit" Diffuse Large B Cell Lymphomas, and Transformed Follicular to Diffuse Large B Cell Lymphomas by Schuster, Stephen J., Svoboda, Jakub, Nasta, Sunita Dwivedy, Chong, Elise A., Winchell, Nicole, Landsburg, Daniel J., Porter, David L., Mato, Anthony R., Strauser, Honore T, Schrank-Hacker, April M., Wasik, Mariusz A, Lacey, Simon Francis, Melenhorst, Jan Joseph, Chew, Anne, Hasskarl, Jens, Marcucci, Katherine T., Levine, Bruce L, June, Carl H

“…BACKGROUND: The cell of origin (COO) of diffuse large B cell lymphoma (DLBCL), germinal center (GC) or non-germinal center (NGC), may have prognostic…”
Get full text

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL by Maude, Shannon L, Barrett, David M., Ambrose, David E, Rheingold, Susan R., Aplenc, Richard, Teachey, David T, Callahan, Colleen, Barker, Christine S, Mudambi, Maya, Shaw, Pamela A, Brogdon, Jennifer, Young, Regina M, Scholler, John, Loew, Andreas, Marcucci, Katherine T., Finklestein, Jeffrey, Kulikovskaya, Irina, Nazimuddin, Farzana, Zheng, Zhaohui, Levine, Bruce L., Porter, David L, Lacey, Simon F., Melenhorst, Jan J., June, Carl H., Grupp, Stephan A.

“…▪ Background Targeted immunotherapy with T cells expressing a chimeric antigen receptor (CAR) can produce dramatic anti-tumor responses. We previously…”
Get full text

Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas by Schuster, Stephen J., Svoboda, Jakub, Dwivedy Nasta, Sunita, Porter, David L., Chong, Elise A., Landsburg, Daniel J., Mato, Anthony R., Lacey, Simon F., Melenhorst, Jan J., Chew, Anne, Hasskarl, Jens, Shah, Gaurav D., Wasik, Mariusz A., Marcucci, Katherine T., Zheng, Zhaohui, Levine, Bruce L., June, Carl H.

“…BACKGROUND: Autologous T cells genetically modified to express a chimeric antigen receptor consisting of an external anti-CD19 single chain antibody domain…”
Get full text

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL by Porter, David L., Lacey, Simon F., Hwang, Wei-Ting, Shaw, Pamela, Frey, Noelle V., Chew, Anne, Chen, Fang, Kalos, Michael, Gonzalez, Vanessa, Marcucci, Katherine T., Maude, Shannon L, Melenhorst, Jan J, Litchman, Manuel, Teachey, David T., Shen, Angela, Quintas-Cardamas, Alfonso, Wood, Patricia A., Levine, Bruce L., June, Carl H., Grupp, Stephan A.

“…CTL019 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) consisting of an external anti-CD19 domain with the CD3z and…”
Get full text

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL by Porter, David L., Frey, Noelle V., Melenhorst, J. Joseph, Hwang, Wei-Ting, Lacey, Simon F., Shaw, Pamela, Chew, Anne, Grupp, Stephan A., Capobianchi, James, Gilmore, Joan, Kalos, Michael, Litchman, Manuel, Lledo, Lester, Loren, Alison Wakoff, Mahnke, Yolanda, Marcucci, Katherine T., McConville, Holly, Shen, Angela, Wood, Patricia A., Zheng, Zhaohui, Levine, Bruce L., June, Carl H.

“…We have shown that infusion of autologous T cells genetically modified to express a chimeric antigen receptor (CAR) consisting of an external anti-CD19 domain,…”
Get full text

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas by Schuster, Stephen J., Svoboda, Jakub, Dwivedy Nasta, Sunita, Porter, David L., Chong, Elise A., Mahnke, Yolanda, Lacey, Simon F., Melenhorst, J. Joseph, Chew, Anne, Shah, Gaurav, Hasskarl, Jens, Litchman, Manuel, Wasik, Mariusz A., Landsburg, Daniel J., Mato, Anthony R., Garfall, Alfred L., Frey, Noelle V., Marcucci, Katherine T., Shea, Joanne, McConville, Holly, Zheng, Zhaohui, Levine, Bruce L., June, Carl H.

“…BACKGROUND: Autologous T cells genetically modified to express a chimeric antigen receptor consisting of an external anti-CD19 single chain antibody domain…”
Get full text